Abstracts tagged "nonsteroidal antiinflammatory drugs (NSAIDs) and spondylarthritis"

Abstract Number: 639 • 2018 ACR/ARHP Annual Meeting
Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Loukianos Couvaras¹, Daniel Wendling², Vanessa Pauly³, Vincent Pradel⁴, Anna Molto⁵, Pierre Lafforgue¹ and Thao Pham⁶, ¹Rheumatology, Aix-Marseille University, APHM, Marseille, France, ²service de rhumatologie, CHU J Minjoz, Besancon, France, ³Public Health, Aix-Marseille university, AP-HM, Marseille, France, ⁴Public Health, APHM, Marseille, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology Department, Aix-Marseille University, APHM, Marseille, France
Background/Purpose: Good response to NSAIDs is a SpA feature included in classification criteria for axial spondyloarthritis (axSpA). Among patients eligible for a TNF inhibitor (TNFi),…
Abstract Number: 1532 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis
Susanne Juhl Pedersen¹, Stephanie Wichuk², Praveena Chiowchanwisawakit³, Robert GW Lambert⁴ and Walter P. Maksymowych², ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Mahidol University, Bangkok, Thailand, ⁴Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Radiography of the sacroiliac joints (SIJ) in spondyloarthritis (SpA) is a valuable diagnostic tool but is unreliable and unresponsive for assessment of treatment effects.…
Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting
Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis
J Sieper¹, M Rudwaleit¹, J Lenaerts², J Wollenhaupt³, L Myasoutova⁴, S Park⁵, Y Song⁶, R Yao⁷, M Govoni⁸, D Chitkara⁹ and N Vastesaeger¹⁰, ¹University Clinic Benjamin Franklin, Berlin, Germany, ²Practice Rheumatology, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴Kazan State Medical University, Kazan, Russia, ⁵Catholic University of Korea, Seoul, South Korea, ⁶Seoul National University, Seoul, South Korea, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].